Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
NCT05145816Phase 2Recruiting
- Sponsor
- UT Southwestern Medical Center
- Start
- Feb 2024
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 2, open-label trial of belantamab mafodotin in amyloid light chain amyloidosis (6 cohorts), sponsored by UT Southwestern Medical Center. Primary endpoint: Dose Limiting Toxicity at 24 weeks. Started Feb 2024; status: recruiting.
02
Drugs
belantamab mafodotin
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT05145816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05145816.